Rezolute (RZLT) Competitors

Rezolute has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Taysha Gene Therapies' return on equity of -56.07% beat Rezolute's return on equity.

In the previous week, Taysha Gene Therapies had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 1 mentions for Rezolute. Rezolute's average media sentiment score of 1.89 beat Taysha Gene Therapies' score of 0.87 indicating that Rezolute is being referred to more favorably in the media.

Rezolute currently has a consensus price target of $9.38, suggesting a potential upside of 97.78%. Taysha Gene Therapies has a consensus price target of $12.62, suggesting a potential upside of 134.49%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Rezolute.

Rezolute has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

83.0% of Rezolute shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Rezolute currently has a consensus price target of $9.38, indicating a potential upside of 97.78%. Rapport Therapeutics has a consensus price target of $57.86, indicating a potential upside of 42.54%. Given Rezolute's higher possible upside, equities research analysts plainly believe Rezolute is more favorable than Rapport Therapeutics.

Rapport Therapeutics' return on equity of -24.78% beat Rezolute's return on equity.

In the previous week, Rapport Therapeutics had 3 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for Rapport Therapeutics and 1 mentions for Rezolute. Rezolute's average media sentiment score of 1.89 beat Rapport Therapeutics' score of 1.66 indicating that Rezolute is being referred to more favorably in the media.

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rezolute has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Rezolute has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Mesoblast's return on equity of 0.00% beat Rezolute's return on equity.

Mesoblast has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

In the previous week, Mesoblast had 9 more articles in the media than Rezolute. MarketBeat recorded 10 mentions for Mesoblast and 1 mentions for Rezolute. Rezolute's average media sentiment score of 1.89 beat Mesoblast's score of 0.77 indicating that Rezolute is being referred to more favorably in the news media.

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rezolute has a consensus price target of $9.38, indicating a potential upside of 97.78%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than Mesoblast.

GH Research is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

GH Research's return on equity of -19.36% beat Rezolute's return on equity.

GH Research has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, GH Research and GH Research both had 1 articles in the media. GH Research's average media sentiment score of 1.89 equaled Rezolute'saverage media sentiment score.

GH Research presently has a consensus price target of $40.38, indicating a potential upside of 59.27%. Rezolute has a consensus price target of $9.38, indicating a potential upside of 97.78%. Given Rezolute's higher probable upside, analysts clearly believe Rezolute is more favorable than GH Research.

56.9% of GH Research shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.